Elekta and Royal Philips have installed a high-field (1.5 Tesla) MR-guided linear accelerator (MR-linac) system, which captures high-quality images of tumours and surrounding tissues, at The Netherlands Cancer Institute (NKI).

MR-linac features the radiotherapy system and a high-field MRI scanner with advanced software that allows a clear and a real-time vision of a patient’s anatomy.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It facilitates an improved targeting of tumour tissue while ensuring a minimal exposure of normal tissue to radiation beams.

"MR imaging is emerging as a promising oncology tool for disease localisation and quantification, therapy planning, treatment guidance, and therapy assessment."

The technology enables physicians to precisely locate a tumour, and lock onto it during delivery, even when tumour tissue is mobile during treatment or changes shape, location or size between treatment sessions.

The Netherlands Cancer Institute department of radiation oncology medical physicist and group leader Professor Uulke van der Heide said: "The ability to actually see that we are delivering the correct radiation dose to the intended target has the potential to reduce side effects and improve quality of life, allow for escalated dose delivery and ultimately increase our ability to control tumours."

The Netherlands Cancer Institute is a member of the Elekta MR-linac Consortium, founded in 2012 by Elekta and technology partner Royal Philips. It is currently the third site to install the MR-linac system.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Philips imaging businesses CEO Rob Cascella said: "In securing that quality and accuracy, MR imaging is emerging as a promising oncology tool for disease localisation and quantification, therapy planning, treatment guidance, and therapy assessment.

"Through the collaboration with Elekta and the consortium partners such as The NKI, I am convinced that we have the prerequisites to make MR-guided radiotherapy a meaningful success for both patients and care providers."

MR-linac system is under functional evaluation at University Medical Center Utrecht, the Netherlands and The University of Texas MD Anderson Cancer Center, Houston, Texas, the US.

By the end of this year, all seven cancer centres taking part in the consortium will have the Elekta MR-linac system installed.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact